Adiposity is commonly associated with adipose tissue dysfunction and many
overnutrition-related
metabolic diseases including
type 2 diabetes. Much attention has been paid to reducing adiposity as a way to improve adipose tissue function and systemic
insulin sensitivity. PFKFB3/iPFK2 is a master regulator of adipocyte nutrient metabolism. Using PFKFB3(+/-) mice, the present study investigated the role of PFKFB3/iPFK2 in regulating diet-induced adiposity and systemic
insulin resistance. On a high-fat diet (HFD), PFKFB3(+/-) mice gained much less
body weight than did wild-type littermates. This was attributed to a smaller increase in adiposity in PFKFB3(+/-) mice than in wild-type controls. However, HFD-induced systemic
insulin resistance was more severe in PFKFB3(+/-) mice than in wild-type littermates. Compared with wild-type littermates, PFKFB3(+/-) mice exhibited increased severity of HFD-induced adipose tissue dysfunction, as evidenced by increased adipose tissue lipolysis, inappropriate
adipokine expression, and decreased
insulin signaling, as well as increased levels of proinflammatory
cytokines in both isolated adipose tissue macrophages and adipocytes. In an in vitro system, knockdown of PFKFB3/iPFK2 in 3T3-L1 adipocytes caused a decrease in the rate of
glucose incorporation into
lipid but an increase in the production of
reactive oxygen species. Furthermore, knockdown of PFKFB3/iPFK2 in 3T3-L1 adipocytes inappropriately altered the expression of
adipokines, decreased
insulin signaling, increased the phosphorylation states of JNK and NFkappaB p65, and enhanced the production of proinflammatory
cytokines. Together, these data suggest that PFKFB3/iPFK2, although contributing to adiposity, protects against diet-induced
insulin resistance and adipose tissue inflammatory response.